Research
A Landmark Study to Measure Parkinson’s
MJFF launched the landmark Parkinson’s Progression Markers Initiative (PPMI) observational
study in 2010 to identify and validate PD biomarkers. Today PPMI is the most comprehensive
Parkinson’s study ever — expanding scientists’ understanding of the disease and pinpointing
new ways to test and monitor PD.
1,500+
VOLUNTEERS
33 SITES
11 COUNTRIES
20 INDUSTRY
PARTNERS
4 CONTINENTS
DIGGING
DEEPER TO
DEFINE PD
The power of the Parkinson’s
Progression Markers Initiative
(PPMI) lies in its unmatched
dataset as a foundation for
deep scientific inquiry and
collaboration.
4,250+ BLOOD
SAMPLES
2,200+ CSF
SAMPLES
1 MILLION+ DATA
DOWNLOADS
130 BIOSAMPLE
65+ PAPERS
2 TRIALS USING
REQUESTS
WITH PPMI DATA PPMI FINDINGS
7
Fall/Winter 2017
Scientists are using PPMI
to define the “molecular
fingerprint” of Parkinson’s
disease through state-of-the-
art “omics” techniques (e.g.,
genomics, proteomics). These
methods look inside body cells
and fluids to identify differences
in people with Parkinson’s —
data that may help scientists
understand what causes PD and
make treatments to prevent or
stop disease.
This fall, MJFF is teaming up
with researchers to use PPMI
and other studies to expand
on this “omics” work. The
expanded scope could enable
greater discovery, and provide
opportunities to compare
findings across studies to verify
results.